Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Arsanis Biosciences has received a grant for the development of monoclonal antibody therapeutics against nosocomial infections from the Austrian Research Promotion Agency, Forschungs-Förderungs-Gesellschaft (FFG).
Subscribe to our email newsletter
FFG will grant 1.19 m EUR in the first year and an additional funding up to 70% of the total budget of 12.5 m EUR will be made over a span of three years.
Arsanis co-founder and chief scientific officer Eszter Nagy said the company is set to establish a wide range of anti-infective antibodies, many of which target nosocomial bacterial infections.
"The FFG grant will support discovery activities of several antibody projects and the pre-clinical and early clinical development of one lead program," Nagy added.